333 related articles for article (PubMed ID: 31286496)
1. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
2. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
[TBL] [Abstract][Full Text] [Related]
3. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
Giovinazzi S; Bellapu D; Morozov VM; Ishov AM
Cell Cycle; 2013 Aug; 12(16):2598-607. PubMed ID: 23907120
[TBL] [Abstract][Full Text] [Related]
4. Mcl-1 dynamics influence mitotic slippage and death in mitosis.
Sloss O; Topham C; Diez M; Taylor S
Oncotarget; 2016 Feb; 7(5):5176-92. PubMed ID: 26769847
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
6. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethality in
Noack S; Raab M; Matthess Y; Sanhaji M; Krämer A; Győrffy B; Kaderali L; El-Balat A; Becker S; Strebhardt K
Oncotarget; 2018 May; 9(40):25842-25859. PubMed ID: 29899826
[TBL] [Abstract][Full Text] [Related]
8. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.
Kuhn E; Wang TL; Doberstein K; Bahadirli-Talbott A; Ayhan A; Sehdev AS; Drapkin R; Kurman RJ; Shih IeM
Mod Pathol; 2016 Oct; 29(10):1254-61. PubMed ID: 27443516
[TBL] [Abstract][Full Text] [Related]
9. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
10. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
11. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
12. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
Etemadmoghadam D; George J; Cowin PA; Cullinane C; Kansara M; ; Gorringe KL; Smyth GK; Bowtell DD
PLoS One; 2010 Nov; 5(11):e15498. PubMed ID: 21103391
[TBL] [Abstract][Full Text] [Related]
13. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
14. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
[TBL] [Abstract][Full Text] [Related]
15. Atypical APC/C-dependent degradation of Mcl-1 provides an apoptotic timer during mitotic arrest.
Allan LA; Skowyra A; Rogers KI; Zeller D; Clarke PR
EMBO J; 2018 Sep; 37(17):. PubMed ID: 29987118
[TBL] [Abstract][Full Text] [Related]
16. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
[TBL] [Abstract][Full Text] [Related]
17. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
18. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
Karst AM; Jones PM; Vena N; Ligon AH; Liu JF; Hirsch MS; Etemadmoghadam D; Bowtell DD; Drapkin R
Cancer Res; 2014 Feb; 74(4):1141-52. PubMed ID: 24366882
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]